Perrigo Reports In-Line Q2 EPS
- ByInvesting.com-
Perrigo (PRGO) reported Q2 EPS of $0.43, in-line with the analyst estimate of $0.43. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06...
Perrigo (PRGO) reported Q2 EPS of $0.43, in-line with the analyst estimate of $0.43. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06...
By Sam BougheddaConsumer self-care products firm Perrigo Company (NYSE:PRGO) announced Monday that its subsidiary, HRA Pharma, has submitted an application to the United States...
Perrigo Company plc's (NYSE: PRGO) HRA Pharma has submitted its application to the FDA for the first-ever over-the-counter (OTC) birth control pill, the first such request for this...
Equity investors will likely seek direction after Friday's disappointing August jobs report amid surging COVID-19 cases in the US, adding another layer of uncertainty to the...
Recent positive news about a COVID-19 vaccine has put the limelight on health-care and pharmaceutical companies, especially BioNTtech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and...
UK Stock News:BP (LON:BP) reported 1Q results: “BP’s first-quarter replacement cost (RC) loss was $485M, compared with a profit of $2,103M a year ago. (…)...
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Strong Sell | Sell | Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Buy | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Neutral | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
4.07 | 9.97 | 1.80 | -5.68 | -58.27% | 300.19M | London | |||
158.50 | 160.80 | 158.10 | -3.35 | -2.07% | 6.50M | London | |||
261.80 | 263.40 | 260.30 | -1.40 | -0.53% | 27.85M | London | |||
447.80 | 449.90 | 441.65 | +5.80 | +1.31% | 36.06M | London | |||
6,674.00 | 6,682.00 | 6,496.00 | +160.0 | +2.46% | 841.02K | London | |||
11,250.00 | 11,292.00 | 10,978.00 | +236.0 | +2.14% | 1.59M | London | |||
81.26 | 83.42 | 81.10 | -2.34 | -2.80% | 26.26M | London | |||
108.60 | 108.80 | 108.60 | 0.00 | 0.00% | 3.05M | London | |||
66.00 | 66.00 | 66.00 | +2.50 | +4.03% | 1.79M | London | |||
270.90 | 272.00 | 268.60 | +0.20 | +0.07% | 10.85M | London | |||
40.95 | 42.00 | 40.95 | -4.50 | -9.78% | 3.63M | London | |||
462.50 | 470.90 | 461.50 | -8.60 | -1.83% | 1.87M | London | |||
66.00 | 66.00 | 66.00 | 0.00 | 0.00% | 22.54K | London | |||
729.80 | 755.60 | 722.20 | 0.00 | 0.00% | 734.42K | London | |||
88.60 | 88.60 | 87.50 | +0.90 | +1.03% | 430.72K | London |